1
|
Sheetikov SA, Khmelevskaya AA, Zornikova KV, Zvyagin IV, Shomuradova AS, Serdyuk YV, Shakirova NT, Peshkova IO, Titov A, Romaniuk DS, Shagina IA, Chudakov DM, Kiryukhin DO, Shcherbakova OV, Khamaganova EG, Dzutseva V, Afanasiev A, Bogolyubova AV, Efimov GA. Clonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein. Front Immunol 2024; 15:1369436. [PMID: 38629062 PMCID: PMC11018901 DOI: 10.3389/fimmu.2024.1369436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2024] [Accepted: 03/19/2024] [Indexed: 04/19/2024] Open
Abstract
Adenovirus vaccines, particularly the COVID-19 Ad5-nCoV adenovirus vaccine, have emerged as promising tools in the fight against infectious diseases. In this study, we investigated the structure of the T cell response to the Spike protein of the SARS-CoV-2 virus used in the COVID-19 Ad5-nCoV adenoviral vaccine in a phase 3 clinical trial (NCT04540419). In 69 participants, we collected peripheral blood samples at four time points after vaccination or placebo injection. Sequencing of T cell receptor repertoires from Spike-stimulated T cell cultures at day 14 from 17 vaccinated revealed a more diverse CD4+ T cell repertoire compared to CD8+. Nevertheless, CD8+ clonotypes accounted for more than half of the Spike-specific repertoire. Our longitudinal analysis showed a peak T cell response at day 14, followed by a decline until month 6. Remarkably, multiple T cell clonotypes persisted for at least 6 months after vaccination, as demonstrated by ex vivo stimulation. Examination of CDR3 regions revealed homologous sequences in both CD4+ and CD8+ clonotypes, with major CD8+ clonotypes sharing high similarity with annotated sequences specific for the NYNYLYRLF peptide, suggesting potential immunodominance. In conclusion, our study demonstrates the immunogenicity of the Ad5-nCoV adenoviral vaccine and highlights its ability to induce robust and durable T cell responses. These findings provide valuable insight into the efficacy of the vaccine against COVID-19 and provide critical information for ongoing efforts to control infectious diseases.
Collapse
Affiliation(s)
- Saveliy A. Sheetikov
- Laboratory of Transplantation Immunology, National Medical Research Center for Hematology, Moscow, Russia
- Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia
| | - Alexandra A. Khmelevskaya
- Laboratory of Transplantation Immunology, National Medical Research Center for Hematology, Moscow, Russia
| | - Ksenia V. Zornikova
- Laboratory of Transplantation Immunology, National Medical Research Center for Hematology, Moscow, Russia
- Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia
| | - Ivan V. Zvyagin
- Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia
- Genomics of Adaptive Immunity Department, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia
| | - Alina S. Shomuradova
- Laboratory of Transplantation Immunology, National Medical Research Center for Hematology, Moscow, Russia
- Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia
| | - Yana V. Serdyuk
- Laboratory of Transplantation Immunology, National Medical Research Center for Hematology, Moscow, Russia
| | - Naina T. Shakirova
- Laboratory of Transplantation Immunology, National Medical Research Center for Hematology, Moscow, Russia
| | - Iuliia O. Peshkova
- Laboratory of Transplantation Immunology, National Medical Research Center for Hematology, Moscow, Russia
| | - Aleksei Titov
- Laboratory of Transplantation Immunology, National Medical Research Center for Hematology, Moscow, Russia
| | - Dmitrii S. Romaniuk
- Laboratory of Transplantation Immunology, National Medical Research Center for Hematology, Moscow, Russia
| | - Irina A. Shagina
- Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia
- Genomics of Adaptive Immunity Department, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia
| | - Dmitry M. Chudakov
- Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia
- Genomics of Adaptive Immunity Department, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia
- Central European Institute of Technology, Masaryk University, Brno, Czechia
| | - Dmitry O. Kiryukhin
- Laboratory of Transplantation Immunology, National Medical Research Center for Hematology, Moscow, Russia
| | - Olga V. Shcherbakova
- Laboratory of Transplantation Immunology, National Medical Research Center for Hematology, Moscow, Russia
| | - Ekaterina G. Khamaganova
- Laboratory of Transplantation Immunology, National Medical Research Center for Hematology, Moscow, Russia
| | - Vitalina Dzutseva
- Novosibirsk State University, Medical School, Novosibirsk, Russia
- NPO Petrovax Pharm LLC, Moscow, Russia
| | | | | | - Grigory A. Efimov
- Laboratory of Transplantation Immunology, National Medical Research Center for Hematology, Moscow, Russia
| |
Collapse
|
2
|
Komissarov AA, Kislova M, Molodtsov IA, Petrenko AA, Dmitrieva E, Okuneva M, Peshkova IO, Shakirova NT, Potashnikova DM, Tvorogova AV, Ptushkin VV, Efimov GA, Nikitin EA, Vasilieva E. Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia. Int J Mol Sci 2022; 24:ijms24010416. [PMID: 36613860 PMCID: PMC9820366 DOI: 10.3390/ijms24010416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Revised: 12/17/2022] [Accepted: 12/20/2022] [Indexed: 12/28/2022] Open
Abstract
The clinical course of the new coronavirus disease 2019 (COVID-19) has shown that patients with chronic lymphocytic leukemia (CLL) are characterized by a high mortality rate, poor response to standard treatment, and low virus-specific antibody response after recovery and/or vaccination. To date, there are no data on the safety and efficacy of the combined vector vaccine Sputnik V in patients with CLL. Here, we analyzed and compared the magnitudes of the antibody and T cell responses after vaccination with the Sputnik V vaccine among healthy donors and individuals with CLL with different statuses of preexposure to coronavirus. We found that vaccination of the COVID-19-recovered individuals resulted in the boosting of pre-existing immune responses in both healthy donors and CLL patients. However, the COVID-19-naïve CLL patients demonstrated a considerably lower antibody response than the healthy donors, although they developed a robust T cell response. Regardless of the previous infection, the individuals over 70 years old demonstrated a decreased response to vaccination, as did those receiving anti-CD20 therapy. In summary, we showed that Sputnik V, like other vaccines, did not induce a robust antibody response in individuals with CLL; however, it provided for the development of a significant anti-COVID-19 T cell response.
Collapse
Affiliation(s)
- Alexey A. Komissarov
- I.V. Davydovsky Clinical City Hospital, Moscow Department of Healthcare, 11/6 Yauzskaya Str., 109240 Moscow, Russia
- Laboratory of Atherothrombosis, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 20 Delegatskaya Str., 127473 Moscow, Russia
- Correspondence: (A.A.K.); (E.V.)
| | - Maria Kislova
- Botkin City Hospital, 5/17 2nd Botkinsky Drive, 125284 Moscow, Russia
| | - Ivan A. Molodtsov
- I.V. Davydovsky Clinical City Hospital, Moscow Department of Healthcare, 11/6 Yauzskaya Str., 109240 Moscow, Russia
| | - Andrei A. Petrenko
- Botkin City Hospital, 5/17 2nd Botkinsky Drive, 125284 Moscow, Russia
- Russian Medical Academy of Continuous Medical Education, 2/1 Barrikadnaya Str., 123242 Moscow, Russia
| | - Elena Dmitrieva
- Botkin City Hospital, 5/17 2nd Botkinsky Drive, 125284 Moscow, Russia
| | - Maria Okuneva
- Botkin City Hospital, 5/17 2nd Botkinsky Drive, 125284 Moscow, Russia
| | - Iuliia O. Peshkova
- National Research Center for Hematology, 4a Novy Zykovsky Proezd, 125167 Moscow, Russia
| | - Naina T. Shakirova
- National Research Center for Hematology, 4a Novy Zykovsky Proezd, 125167 Moscow, Russia
| | - Daria M. Potashnikova
- I.V. Davydovsky Clinical City Hospital, Moscow Department of Healthcare, 11/6 Yauzskaya Str., 109240 Moscow, Russia
| | - Anna V. Tvorogova
- I.V. Davydovsky Clinical City Hospital, Moscow Department of Healthcare, 11/6 Yauzskaya Str., 109240 Moscow, Russia
| | - Vadim V. Ptushkin
- Botkin City Hospital, 5/17 2nd Botkinsky Drive, 125284 Moscow, Russia
| | - Grigory A. Efimov
- National Research Center for Hematology, 4a Novy Zykovsky Proezd, 125167 Moscow, Russia
| | - Eugene A. Nikitin
- Botkin City Hospital, 5/17 2nd Botkinsky Drive, 125284 Moscow, Russia
- Russian Medical Academy of Continuous Medical Education, 2/1 Barrikadnaya Str., 123242 Moscow, Russia
| | - Elena Vasilieva
- I.V. Davydovsky Clinical City Hospital, Moscow Department of Healthcare, 11/6 Yauzskaya Str., 109240 Moscow, Russia
- Laboratory of Atherothrombosis, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 20 Delegatskaya Str., 127473 Moscow, Russia
- Correspondence: (A.A.K.); (E.V.)
| |
Collapse
|
3
|
Aghayev T, Mazitova AM, Fang JR, Peshkova IO, Rausch M, Hung M, White KF, Masia R, Titerina EK, Fatkhullina AR, Cousineau I, Turcotte S, Zhigarev D, Marchenko A, Khoziainova S, Makhov P, Tan YF, Kossenkov AV, Wiest DL, Stagg J, Wang XW, Campbell KS, Dzutsev AK, Trinchieri G, Hill JA, Grivennikov SI, Koltsova EK. IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma. Cancer Discov 2022; 12:1960-1983. [PMID: 35723626 PMCID: PMC9357073 DOI: 10.1158/2159-8290.cd-20-1628] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2020] [Revised: 04/01/2022] [Accepted: 06/03/2022] [Indexed: 02/07/2023]
Abstract
Although inflammatory mechanisms driving hepatocellular carcinoma (HCC) have been proposed, the regulators of anticancer immunity in HCC remain poorly understood. We found that IL27 receptor (IL27R) signaling promotes HCC development in vivo. High IL27EBI3 cytokine or IL27RA expression correlated with poor prognosis for patients with HCC. Loss of IL27R suppressed HCC in vivo in two different models of hepatocarcinogenesis. Mechanistically, IL27R sig-naling within the tumor microenvironment restrains the cytotoxicity of innate cytotoxic lymphocytes. IL27R ablation enhanced their accumulation and activation, whereas depletion or functional impairment of innate cytotoxic cells abrogated the effect of IL27R disruption. Pharmacologic neutralization of IL27 signaling increased infiltration of innate cytotoxic lymphocytes with upregulated cytotoxic molecules and reduced HCC development. Our data reveal an unexpected role of IL27R signaling as an immunologic checkpoint regulating innate cytotoxic lymphocytes and promoting HCC of different etiologies, thus indicating a therapeutic potential for IL27 pathway blockade in HCC. SIGNIFICANCE HCC, the most common form of liver cancer, is characterized by a poor survival rate and limited treatment options. The discovery of a novel IL27-dependent mechanism controlling anticancer cytotoxic immune response will pave the road for new treatment options for this devastating disease. This article is highlighted in the In This Issue feature, p. 1825.
Collapse
Affiliation(s)
- Turan Aghayev
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
| | - Aleksandra M. Mazitova
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA,Cedars-Sinai Medical Center, Cedars-Sinai Cancer Institute, Department of Medicine, Department of Biomedical Sciences 8700 Beverly Blvd, Los Angeles, CA, 900048
| | - Jennifer R. Fang
- Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA, 20892
| | - Iuliia O. Peshkova
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
| | - Matthew Rausch
- Surface Oncology Inc., 50 Hampshire St. Cambridge, MA, 02139
| | - Manhsin Hung
- Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA, 20892,Liver Cancer Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA, 20892
| | - Kerry F. White
- Surface Oncology Inc., 50 Hampshire St. Cambridge, MA, 02139
| | - Ricard Masia
- Surface Oncology Inc., 50 Hampshire St. Cambridge, MA, 02139
| | - Elizaveta K. Titerina
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
| | - Aliia R. Fatkhullina
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
| | - Isabelle Cousineau
- Centre Hospitalier de l’Université de Montréal Research Center, Montreal, Quebec, Canada
| | - Simon Turcotte
- Centre Hospitalier de l’Université de Montréal Research Center, Montreal, Quebec, Canada
| | - Dmitry Zhigarev
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
| | - Anastasiia Marchenko
- Cedars-Sinai Medical Center, Cedars-Sinai Cancer Institute, Department of Medicine, Department of Biomedical Sciences 8700 Beverly Blvd, Los Angeles, CA, 900048
| | - Svetlana Khoziainova
- Cedars-Sinai Medical Center, Cedars-Sinai Cancer Institute, Department of Medicine, Department of Biomedical Sciences 8700 Beverly Blvd, Los Angeles, CA, 900048
| | - Petr Makhov
- Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA
| | - Yin Fei Tan
- Genomics Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
| | | | - David L. Wiest
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
| | - John Stagg
- Centre Hospitalier de l’Université de Montréal Research Center, Montreal, Quebec, Canada
| | - Xin Wei Wang
- Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA, 20892,Liver Cancer Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA, 20892
| | - Kerry S. Campbell
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
| | - Amiran K. Dzutsev
- Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA, 20892
| | - Giorgio Trinchieri
- Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA, 20892
| | | | - Sergei I. Grivennikov
- Cedars-Sinai Medical Center, Cedars-Sinai Cancer Institute, Department of Medicine, Department of Biomedical Sciences 8700 Beverly Blvd, Los Angeles, CA, 900048,Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA
| | - Ekaterina K. Koltsova
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA,Cedars-Sinai Medical Center, Cedars-Sinai Cancer Institute, Department of Medicine, Department of Biomedical Sciences 8700 Beverly Blvd, Los Angeles, CA, 900048,Corresponding and Lead Author, contact: Ekaterina Koltsova, MD, PhD, Department of Medicine, Department of Biomedical Sciences, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 900048, USA., phone: +1-310-423-8899,
| |
Collapse
|
4
|
Molodtsov IA, Kegeles E, Mitin AN, Mityaeva O, Musatova OE, Panova AE, Pashenkov MV, Peshkova IO, Alsalloum A, Asaad W, Budikhina AS, Deryabin AS, Dolzhikova IV, Filimonova IN, Gracheva AN, Ivanova OI, Kizilova A, Komogorova VV, Komova A, Kompantseva NI, Kucheryavykh E, Lagutkin DA, Lomakin YA, Maleeva AV, Maryukhnich EV, Mohammad A, Murugin VV, Murugina NE, Navoikova A, Nikonova MF, Ovchinnikova LA, Panarina Y, Pinegina NV, Potashnikova DM, Romanova EV, Saidova AA, Sakr N, Samoilova AG, Serdyuk Y, Shakirova NT, Sharova NI, Sheetikov SA, Shemetova AF, Shevkova LV, Shpektor AV, Trufanova A, Tvorogova AV, Ukrainskaya VM, Vinokurov AS, Vorobyeva DA, Zornikova KV, Efimov GA, Khaitov MR, Kofiadi IA, Komissarov AA, Logunov DY, Naigovzina NB, Rubtsov YP, Vasilyeva IA, Volchkov P, Vasilieva E. SARS-CoV-2-specific T cells and antibodies in COVID-19 protection: a prospective study. Clin Infect Dis 2022; 75:e1-e9. [PMID: 35435222 PMCID: PMC9047235 DOI: 10.1093/cid/ciac278] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Indexed: 12/12/2022] Open
Abstract
Background During the ongoing coronavirus disease 2019 (COVID-19) pandemic, many individuals were infected with and have cleared the virus, developing virus-specific antibodies and effector/memory T cells. An important unanswered question is what levels of T-cell and antibody responses are sufficient to protect from the infection. Methods In 5340 Moscow residents, we evaluated anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin M (IgM)/immunoglobulin G (IgG) titers and frequencies of the T cells specific to the membrane, nucleocapsid, and spike proteins of SARS-CoV-2, using interferon gamma (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) assay. Additionally, we evaluated the fractions of virus-specific CD4+ and CD8+ T cells using intracellular staining of IFN-γ and interleukin 2 followed by flow cytometry. We analyzed the COVID-19 rates as a function of the assessed antibody and T-cell responses, using the Kaplan–Meier estimator method, for up to 300 days postinclusion. Results We showed that T-cell and antibody responses are closely interconnected and are commonly induced concurrently. Magnitudes of both responses inversely correlated with infection probability. Individuals positive for both responses demonstrated the highest levels of protectivity against the SARS-CoV-2 infection. A comparable level of protection was found in individuals with antibody response only, whereas the T-cell response by itself granted only intermediate protection. Conclusions We found that the contribution of the virus-specific antibodies to protection against SARS-CoV-2 infection is more pronounced than that of the T cells. The data on the virus-specific IgG titers may be instructive for making decisions in personalized healthcare and public anti–COVID-19 policies. Clinical Trials Registration. NCT04898140.
Collapse
Affiliation(s)
- Ivan A Molodtsov
- Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, 109240, 11/6 Yauzskaya str., Moscow, Russia
| | - Evgenii Kegeles
- Genome Engineering lab, Moscow Institute of Physics and Technology, 141700, 9 Institutskiy per., Dolgoprudniy, Russia
| | - Alexander N Mitin
- National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522, 24 Kashirskoye shosse, Moscow, Russia
| | - Olga Mityaeva
- Genome Engineering lab, Moscow Institute of Physics and Technology, 141700, 9 Institutskiy per., Dolgoprudniy, Russia
| | - Oksana E Musatova
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997, 16/10 Miklukho-Maklaya str., Moscow, Russia
| | - Anna E Panova
- National Medical Research Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, 127473, 4 Dostoevsky str., Moscow, Russia
| | - Mikhail V Pashenkov
- National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522, 24 Kashirskoye shosse, Moscow, Russia
| | - Iuliia O Peshkova
- National Medical Research Center for Hematology, 125167, 4a Novy Zykovsky proezd, Moscow, Russia
| | - Almaqdad Alsalloum
- Genome Engineering lab, Moscow Institute of Physics and Technology, 141700, 9 Institutskiy per., Dolgoprudniy, Russia
| | - Walaa Asaad
- Genome Engineering lab, Moscow Institute of Physics and Technology, 141700, 9 Institutskiy per., Dolgoprudniy, Russia
| | - Anna S Budikhina
- National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522, 24 Kashirskoye shosse, Moscow, Russia
| | - Alexander S Deryabin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997, 16/10 Miklukho-Maklaya str., Moscow, Russia
| | - Inna V Dolzhikova
- Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya" of the Ministry of Health of the Russian Federation, 123098, 18 Gamaleya str., Moscow, Russia
| | - Ioanna N Filimonova
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997, 16/10 Miklukho-Maklaya str., Moscow, Russia
| | - Alexandra N Gracheva
- National Medical Research Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, 127473, 4 Dostoevsky str., Moscow, Russia
| | - Oxana I Ivanova
- Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, 109240, 11/6 Yauzskaya str., Moscow, Russia.,A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 127473, 20 Delegatskaya str., Moscow, Russia
| | - Anastasia Kizilova
- Genome Engineering lab, Moscow Institute of Physics and Technology, 141700, 9 Institutskiy per., Dolgoprudniy, Russia
| | - Viktoria V Komogorova
- National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522, 24 Kashirskoye shosse, Moscow, Russia
| | - Anastasia Komova
- Genome Engineering lab, Moscow Institute of Physics and Technology, 141700, 9 Institutskiy per., Dolgoprudniy, Russia.,Research Institute of Personalized Medicine, National Center for Personalized Medicine of Endocrine Diseases, The National Medical Research Center for Endocrinology, 117036, 11 Dmitry Ulyanov str., Moscow, Russia
| | - Natalia I Kompantseva
- National Medical Research Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, 127473, 4 Dostoevsky str., Moscow, Russia
| | | | - Denis A Lagutkin
- National Medical Research Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, 127473, 4 Dostoevsky str., Moscow, Russia
| | - Yakov A Lomakin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997, 16/10 Miklukho-Maklaya str., Moscow, Russia
| | - Alexandra V Maleeva
- National Medical Research Center for Hematology, 125167, 4a Novy Zykovsky proezd, Moscow, Russia
| | - Elena V Maryukhnich
- Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, 109240, 11/6 Yauzskaya str., Moscow, Russia.,A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 127473, 20 Delegatskaya str., Moscow, Russia
| | - Afraa Mohammad
- Genome Engineering lab, Moscow Institute of Physics and Technology, 141700, 9 Institutskiy per., Dolgoprudniy, Russia
| | - Vladimir V Murugin
- National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522, 24 Kashirskoye shosse, Moscow, Russia
| | - Nina E Murugina
- National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522, 24 Kashirskoye shosse, Moscow, Russia
| | - Anna Navoikova
- Genome Engineering lab, Moscow Institute of Physics and Technology, 141700, 9 Institutskiy per., Dolgoprudniy, Russia
| | - Margarita F Nikonova
- National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522, 24 Kashirskoye shosse, Moscow, Russia
| | - Leyla A Ovchinnikova
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997, 16/10 Miklukho-Maklaya str., Moscow, Russia
| | - Yana Panarina
- The Government of Moscow, 125032, 13 Tverskaya str., Moscow, Russia
| | - Natalia V Pinegina
- Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, 109240, 11/6 Yauzskaya str., Moscow, Russia.,A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 127473, 20 Delegatskaya str., Moscow, Russia
| | - Daria M Potashnikova
- Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, 109240, 11/6 Yauzskaya str., Moscow, Russia.,A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 127473, 20 Delegatskaya str., Moscow, Russia
| | - Elizaveta V Romanova
- Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, 109240, 11/6 Yauzskaya str., Moscow, Russia
| | - Aleena A Saidova
- Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, 109240, 11/6 Yauzskaya str., Moscow, Russia
| | - Nawar Sakr
- Genome Engineering lab, Moscow Institute of Physics and Technology, 141700, 9 Institutskiy per., Dolgoprudniy, Russia
| | - Anastasia G Samoilova
- National Medical Research Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, 127473, 4 Dostoevsky str., Moscow, Russia
| | - Yana Serdyuk
- National Medical Research Center for Hematology, 125167, 4a Novy Zykovsky proezd, Moscow, Russia
| | - Naina T Shakirova
- National Medical Research Center for Hematology, 125167, 4a Novy Zykovsky proezd, Moscow, Russia
| | - Nina I Sharova
- National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522, 24 Kashirskoye shosse, Moscow, Russia
| | - Saveliy A Sheetikov
- National Medical Research Center for Hematology, 125167, 4a Novy Zykovsky proezd, Moscow, Russia
| | - Anastasia F Shemetova
- National Medical Research Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, 127473, 4 Dostoevsky str., Moscow, Russia
| | - Liudmila V Shevkova
- Genome Engineering lab, Moscow Institute of Physics and Technology, 141700, 9 Institutskiy per., Dolgoprudniy, Russia.,Research Institute of Personalized Medicine, National Center for Personalized Medicine of Endocrine Diseases, The National Medical Research Center for Endocrinology, 117036, 11 Dmitry Ulyanov str., Moscow, Russia
| | - Alexander V Shpektor
- Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, 109240, 11/6 Yauzskaya str., Moscow, Russia.,A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 127473, 20 Delegatskaya str., Moscow, Russia
| | - Anna Trufanova
- Genome Engineering lab, Moscow Institute of Physics and Technology, 141700, 9 Institutskiy per., Dolgoprudniy, Russia
| | - Anna V Tvorogova
- Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, 109240, 11/6 Yauzskaya str., Moscow, Russia
| | - Valeria M Ukrainskaya
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997, 16/10 Miklukho-Maklaya str., Moscow, Russia
| | - Anatoliy S Vinokurov
- National Medical Research Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, 127473, 4 Dostoevsky str., Moscow, Russia
| | - Daria A Vorobyeva
- Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, 109240, 11/6 Yauzskaya str., Moscow, Russia.,A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 127473, 20 Delegatskaya str., Moscow, Russia
| | - Ksenia V Zornikova
- National Medical Research Center for Hematology, 125167, 4a Novy Zykovsky proezd, Moscow, Russia
| | - Grigory A Efimov
- National Medical Research Center for Hematology, 125167, 4a Novy Zykovsky proezd, Moscow, Russia
| | - Musa R Khaitov
- National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522, 24 Kashirskoye shosse, Moscow, Russia.,Pirogov Russian National Research Medical University, 119997, 1 Ostrovityanov str., Moscow, Russia
| | - Ilya A Kofiadi
- National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522, 24 Kashirskoye shosse, Moscow, Russia.,Pirogov Russian National Research Medical University, 119997, 1 Ostrovityanov str., Moscow, Russia
| | - Alexey A Komissarov
- Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, 109240, 11/6 Yauzskaya str., Moscow, Russia.,A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 127473, 20 Delegatskaya str., Moscow, Russia
| | - Denis Y Logunov
- Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya" of the Ministry of Health of the Russian Federation, 123098, 18 Gamaleya str., Moscow, Russia
| | - Nelli B Naigovzina
- A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 127473, 20 Delegatskaya str., Moscow, Russia
| | - Yury P Rubtsov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997, 16/10 Miklukho-Maklaya str., Moscow, Russia
| | - Irina A Vasilyeva
- National Medical Research Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, 127473, 4 Dostoevsky str., Moscow, Russia
| | - Pavel Volchkov
- Genome Engineering lab, Moscow Institute of Physics and Technology, 141700, 9 Institutskiy per., Dolgoprudniy, Russia.,Research Institute of Personalized Medicine, National Center for Personalized Medicine of Endocrine Diseases, The National Medical Research Center for Endocrinology, 117036, 11 Dmitry Ulyanov str., Moscow, Russia
| | - Elena Vasilieva
- Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, 109240, 11/6 Yauzskaya str., Moscow, Russia.,A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 127473, 20 Delegatskaya str., Moscow, Russia
| |
Collapse
|
5
|
Komissarov AA, Dolzhikova IV, Efimov GA, Logunov DY, Mityaeva O, Molodtsov IA, Naigovzina NB, Peshkova IO, Shcheblyakov DV, Volchkov P, Gintsburg AL, Vasilieva E. Boosting of the SARS-CoV-2-Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine. J Immunol 2022; 208:1139-1145. [PMID: 35101893 DOI: 10.4049/jimmunol.2101052] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Accepted: 12/16/2021] [Indexed: 12/21/2022]
Abstract
Despite measures taken world-wide, the coronavirus disease 2019 (COVID-19) pandemic continues. Because efficient antiviral drugs are not yet widely available, vaccination is the best option to control the infection rate. Although this option is obvious in the case of COVID-19-naive individuals, it is still unclear when individuals who have recovered from a previous SARS-CoV-2 infection should be vaccinated and whether the vaccination raises immune responses against the coronavirus and its novel variants. In this study, we collected peripheral blood from 84 healthy human donors of different COVID-19 status who were vaccinated with the Sputnik Light vaccine and measured the dynamics of the Ab and T cell responses, as well as the virus-neutralizing activity (VNA) in serum, against two SARS-CoV-2 variants, B.1.1.1 and B.1.617.2. We showed that vaccination of individuals previously exposed to the virus considerably boosts the existing immune response. In these individuals, receptor-binding domain (RBD)-specific IgG titers and VNA in serum were already elevated on the 7th day after vaccination, whereas COVID-19-naive individuals developed the Ab response and VNA mainly 21 d postvaccination. Additionally, we found a strong correlation between RBD-specific IgG titers and VNA in serum, and according to these data vaccination may be recommended when the RBD-specific IgG titers drop to 142.7 binding Ab units/ml or below. In summary, the results of the study demonstrate that vaccination is beneficial for both COVID-19-naive and recovered individuals, especially since it raises serum VNA against the B.1.617.2 variant, one of the five SARS-CoV-2 variants of concern.
Collapse
Affiliation(s)
- Alexey A Komissarov
- Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, Moscow, Russia;
| | - Inna V Dolzhikova
- Federal State Budget Institution National Research Centre for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation, Moscow, Russia
| | | | - Denis Y Logunov
- Federal State Budget Institution National Research Centre for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Olga Mityaeva
- Genome Engineering Laboratory, Moscow Institute of Physics and Technology, Dolgoprudniy, Russia
| | - Ivan A Molodtsov
- Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, Moscow, Russia
| | - Nelli B Naigovzina
- A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia; and
| | | | - Dmitry V Shcheblyakov
- Federal State Budget Institution National Research Centre for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Pavel Volchkov
- Genome Engineering Laboratory, Moscow Institute of Physics and Technology, Dolgoprudniy, Russia.,Research Institute of Personalized Medicine, National Center for Personalized Medicine of Endocrine Diseases, The National Medical Research Center for Endocrinology, Moscow, Russia
| | - Alexander L Gintsburg
- Federal State Budget Institution National Research Centre for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Elena Vasilieva
- Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, Moscow, Russia.,A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia; and
| |
Collapse
|
6
|
Shomuradova AS, Vagida MS, Sheetikov SA, Zornikova KV, Kiryukhin D, Titov A, Peshkova IO, Khmelevskaya A, Dianov DV, Malasheva M, Shmelev A, Serdyuk Y, Bagaev DV, Pivnyuk A, Shcherbinin DS, Maleeva AV, Shakirova NT, Pilunov A, Malko DB, Khamaganova EG, Biderman B, Ivanov A, Shugay M, Efimov GA. SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors. Immunity 2020; 53:1245-1257.e5. [PMID: 33326767 PMCID: PMC7664363 DOI: 10.1016/j.immuni.2020.11.004] [Citation(s) in RCA: 140] [Impact Index Per Article: 35.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2020] [Revised: 09/02/2020] [Accepted: 11/09/2020] [Indexed: 12/28/2022]
Abstract
Understanding the hallmarks of the immune response to SARS-CoV-2 is critical for fighting the COVID-19 pandemic. We assessed antibody and T cell reactivity in convalescent COVID-19 patients and healthy donors sampled both prior to and during the pandemic. Healthy donors examined during the pandemic exhibited increased numbers of SARS-CoV-2-specific T cells, but no humoral response. Their probable exposure to the virus resulted in either asymptomatic infection without antibody secretion or activation of preexisting immunity. In convalescent patients, we observed a public and diverse T cell response to SARS-CoV-2 epitopes, revealing T cell receptor (TCR) motifs with germline-encoded features. Bulk CD4+ and CD8+ T cell responses to the spike protein were mediated by groups of homologous TCRs, some of them shared across multiple donors. Overall, our results demonstrate that the T cell response to SARS-CoV-2, including the identified set of TCRs, can serve as a useful biomarker for surveying antiviral immunity.
Collapse
Affiliation(s)
- Alina S Shomuradova
- National Research Center for Hematology, Moscow, Russia; Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia
| | | | - Savely A Sheetikov
- National Research Center for Hematology, Moscow, Russia; Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia
| | - Ksenia V Zornikova
- National Research Center for Hematology, Moscow, Russia; Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia
| | | | - Aleksei Titov
- National Research Center for Hematology, Moscow, Russia
| | | | - Alexandra Khmelevskaya
- National Research Center for Hematology, Moscow, Russia; Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia
| | - Dmitry V Dianov
- National Research Center for Hematology, Moscow, Russia; Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia
| | - Maria Malasheva
- National Research Center for Hematology, Moscow, Russia; Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia
| | - Anton Shmelev
- National Research Center for Hematology, Moscow, Russia
| | - Yana Serdyuk
- National Research Center for Hematology, Moscow, Russia
| | - Dmitry V Bagaev
- Eindhoven University of Technology, Eindhoven, the Netherlands
| | - Anastasia Pivnyuk
- Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, Russia
| | - Dmitrii S Shcherbinin
- Pirogov Russian Medical State University, Moscow, Russia; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia
| | | | | | - Artem Pilunov
- National Research Center for Hematology, Moscow, Russia; Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia
| | | | | | | | - Alexander Ivanov
- Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia
| | - Mikhail Shugay
- Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, Russia; Pirogov Russian Medical State University, Moscow, Russia; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia.
| | | |
Collapse
|
7
|
Peshkova IO, Aghayev T, Fatkhullina AR, Makhov P, Titerina EK, Eguchi S, Tan YF, Kossenkov AV, Khoreva MV, Gankovskaya LV, Sykes SM, Koltsova EK. IL-27 receptor-regulated stress myelopoiesis drives abdominal aortic aneurysm development. Nat Commun 2019; 10:5046. [PMID: 31695038 PMCID: PMC6834661 DOI: 10.1038/s41467-019-13017-4] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2018] [Accepted: 10/15/2019] [Indexed: 02/07/2023] Open
Abstract
Abdominal aortic aneurysm (AAA) is a prevalent life-threatening disease, where aortic wall degradation is mediated by accumulated immune cells. Although cytokines regulate inflammation within the aorta, their contribution to AAA via distant alterations, particularly in the control of hematopoietic stem cell (HSC) differentiation, remains poorly defined. Here we report a pathogenic role for the interleukin-27 receptor (IL-27R) in AAA, as genetic ablation of IL-27R protects mice from the disease development. Mitigation of AAA is associated with a blunted accumulation of myeloid cells in the aorta due to the attenuation of Angiotensin II (Ang II)-induced HSC expansion. IL-27R signaling is required to induce transcriptional programming to overcome HSC quiescence and increase differentiation and output of mature myeloid cells in response to stress stimuli to promote their accumulation in the diseased aorta. Overall, our studies illuminate how a prominent vascular disease can be distantly driven by a cytokine-dependent regulation of bone marrow precursors.
Collapse
Affiliation(s)
- Iuliia O Peshkova
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, USA
- Pirogov Russian National Research Medical University, Moscow, 117997, Russia
| | - Turan Aghayev
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, USA
- Pirogov Russian National Research Medical University, Moscow, 117997, Russia
| | - Aliia R Fatkhullina
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, USA
| | - Petr Makhov
- Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, USA
| | - Elizaveta K Titerina
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, USA
- Pirogov Russian National Research Medical University, Moscow, 117997, Russia
| | - Satoru Eguchi
- Lewis Katz School of Medicine, Temple University Cardiovascular Research Center, Philadelphia, Pennsylvania, 19140, USA
| | - Yin Fei Tan
- Genomics Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, USA
| | - Andrew V Kossenkov
- Bioinformatics Facility, The Wistar Institute, Philadelphia, Pennsylvania, 19104, USA
| | - Marina V Khoreva
- Pirogov Russian National Research Medical University, Moscow, 117997, Russia
| | | | - Stephen M Sykes
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, USA
| | - Ekaterina K Koltsova
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, USA.
| |
Collapse
|
8
|
Fatkhullina AR, Peshkova IO, Dzutsev A, Aghayev T, McCulloch JA, Thovarai V, Badger JH, Vats R, Sundd P, Tang HY, Kossenkov AV, Hazen SL, Trinchieri G, Grivennikov SI, Koltsova EK. An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis. Immunity 2018; 49:943-957.e9. [PMID: 30389414 PMCID: PMC6257980 DOI: 10.1016/j.immuni.2018.09.011] [Citation(s) in RCA: 106] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Revised: 06/20/2018] [Accepted: 09/13/2018] [Indexed: 12/20/2022]
Abstract
Although commensal flora is involved in the regulation of immunity, the interplay between cytokine signaling and microbiota in atherosclerosis remains unknown. We found that interleukin (IL)-23 and its downstream target IL-22 restricted atherosclerosis by repressing pro-atherogenic microbiota. Inactivation of IL-23-IL-22 signaling led to deterioration of the intestinal barrier, dysbiosis, and expansion of pathogenic bacteria with distinct biosynthetic and metabolic properties, causing systemic increase in pro-atherogenic metabolites such as lipopolysaccharide (LPS) and trimethylamine N-oxide (TMAO). Augmented disease in the absence of the IL-23-IL-22 pathway was mediated in part by pro-atherogenic osteopontin, controlled by microbial metabolites. Microbiota transfer from IL-23-deficient mice accelerated atherosclerosis, whereas microbial depletion or IL-22 supplementation reduced inflammation and ameliorated disease. Our work uncovers the IL-23-IL-22 signaling as a regulator of atherosclerosis that restrains expansion of pro-atherogenic microbiota and argues for informed use of cytokine blockers to avoid cardiovascular side effects driven by microbiota and inflammation.
Collapse
Affiliation(s)
- Aliia R Fatkhullina
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA
| | - Iuliia O Peshkova
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA
| | - Amiran Dzutsev
- Cancer and Inflammation Program, Center for Cancer Research, NCI, NIH, Frederick National Laboratory for Cancer Research sponsored by the NCI, Bethesda, MD, 20892, USA
| | - Turan Aghayev
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA
| | - John A McCulloch
- Cancer and Inflammation Program, Center for Cancer Research, NCI, NIH, Frederick National Laboratory for Cancer Research sponsored by the NCI, Bethesda, MD, 20892, USA
| | - Vishal Thovarai
- Cancer and Inflammation Program, Center for Cancer Research, NCI, NIH, Frederick National Laboratory for Cancer Research sponsored by the NCI, Bethesda, MD, 20892, USA; Basic Science Program, Frederick National Laboratory for Cancer Research sponsored by the NCI, Bethesda, MD, 20892, USA
| | - Jonathan H Badger
- Cancer and Inflammation Program, Center for Cancer Research, NCI, NIH, Frederick National Laboratory for Cancer Research sponsored by the NCI, Bethesda, MD, 20892, USA
| | - Ravi Vats
- Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA
| | - Prithu Sundd
- Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA
| | - Hsin-Yao Tang
- Proteomics and Metabolomics, The Wistar Institute, Philadelphia, PA, 19104, USA
| | - Andrew V Kossenkov
- Bioinformatics Facilities, The Wistar Institute, Philadelphia, PA, 19104, USA
| | - Stanley L Hazen
- Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA
| | - Giorgio Trinchieri
- Cancer and Inflammation Program, Center for Cancer Research, NCI, NIH, Frederick National Laboratory for Cancer Research sponsored by the NCI, Bethesda, MD, 20892, USA
| | - Sergei I Grivennikov
- Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA
| | - Ekaterina K Koltsova
- Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
| |
Collapse
|
9
|
Abstract
Atherosclerosis contributes to the development of many cardiovascular diseases, which remain the leading cause of death in developed countries. Atherosclerosis is a chronic inflammatory disease of large and medium-sized arteries. It is caused by dyslipidemia and mediated by both innate and adaptive immune responses. Inflammation is a key factor at all stages of atherosclerosis progression. Cells involved in pathogenesis of atherosclerosis were shown to be activated by soluble factors, cytokines, that strongly influence the disease development. Pro-inflammatory cytokines accelerate atherosclerosis progression, while anti-inflammatory cytokines ameliorate the disease. In this review, we discuss the latest findings on the role of cytokines in the development and progression of atherosclerosis.
Collapse
|
10
|
Peshkova IO, Schaefer G, Koltsova EK. Atherosclerosis and aortic aneurysm – is inflammation a common denominator? FEBS J 2016; 283:1636-52. [DOI: 10.1111/febs.13634] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2015] [Revised: 11/20/2015] [Accepted: 12/18/2015] [Indexed: 12/30/2022]
Affiliation(s)
- Iuliia O. Peshkova
- Blood Cell Development and Function Program Fox Chase Cancer Center Philadephia PA USA
| | - Giulia Schaefer
- Blood Cell Development and Function Program Fox Chase Cancer Center Philadephia PA USA
| | - Ekaterina K. Koltsova
- Blood Cell Development and Function Program Fox Chase Cancer Center Philadephia PA USA
| |
Collapse
|